8-K/A 1 0001.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 10, 2000 --------------- SANGUI BIOTECH INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Colorado (State or other jurisdiction of incorporation) 0-21271 84-1330732 ---------------- ------------------------ (Commission File Number) (IRS Employer Identification No.) 1508 BROOKHOLLOW DRIVE, SUITE 354 SANTA ANA, CALIFORNIA 92705 -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) (714) 429-7807 ------------------------- Registrant's telephone number, including area code: Not applicable --------------------------------- (Former name, address and telephone number) 1 ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT Effective July 10, 2000, the Board of Directors of the Company approved the engagement of Corbin & Wertz Certified Public Accountants as its independent auditors for the fiscal year ending June 30, 2000 to replace Ernst & Young Deutsche Allgemeine Treuhand AG Wirtschaftsprufungsgesellschaft (Ernst & Young) who declined to stand for reelection. The report of Ernst & Young on the Company's financial statements for the six months ended June 30, 1999 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. In connection with the audit of the Company's financial statements for the six months ending June 30, 1999, and in the subsequent interim period preceding the date Ernst & Young declined to stand for reelection, there were no disagreements with Ernst & Young on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures which, if not resolved to the satisfaction of Ernst & Young would have caused Ernst & Young to make reference to the matter in their report. The Company has requested Ernst & Young to furnish it a letter addressed to the Commission stating whether it agrees with the above statements. A copy of that letter, dated August 3, 2000 is filed as Exhibit 1 to this Form 8-K/A. EXHIBITS 16.1 LETTER DATED AUGUST 3, 2000, FROM ERNST & YOUNG REGARDING ITS CONCURRENCE WITH THE STATEMENTS MADE BY THE REGISTRANT IN THIS CURRENT REPORT. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. SANGUI BIOTECH INTERNATIONAL, INC. /s/ Wolfgang Barnikol ---------------------------------- President and Chief Executive Officer Date: August 3, 2000